BGT007 Cells for the Treatment of Refractory Digestive System Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 22, 2023

Primary Completion Date

October 20, 2026

Study Completion Date

October 20, 2027

Conditions
Gastrointestinal Cancer
Interventions
BIOLOGICAL

BGT007 Injection

BGT007 injection (d0) were infused intravenously once, and the dose group was 5.0× 10\^7 cells,1.0 ×10\^8 cells, 3.0× 10\^8 cells,1.0 × 10\^9 cells,3.0 ×10\^9 cells.

Trial Locations (1)

221000

RECRUITING

he Affiliated Hospital of Xuzhou Medical University, Xuzhou

All Listed Sponsors
collaborator

Guangzhou Bioresette Biomedical Technology Co., Ltd.

INDUSTRY

lead

The Affiliated Hospital of Xuzhou Medical University

OTHER